Syntara Limited has released a press release.
Pharmaxis Announces Russian Approval for Bronchitol
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Pharmaxis Completes Recruitment of CF Clinical Trial for US
- Appendix 4C - quarterly March 2016
- US FDA Accepts Bronchitol New Drug Application for Review
- Quarterly Share Update - December 2015
- Bronchitol Paediatric CF Trial Reports Postive Results
Later from Syntara
- S&P DJ Indicies Announces March Quarterly Rebalance
- Research Collaboration with Woolcock Institute
- Chairmans Address to Shareholders
- Synairgen Collaboration Progress
- Quarterly Shareholder Update March 2017
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara